Evidence map›Paper›PMID 26286575›Full record

ArticleThe Journal of antimicrobial chemotherapy2015

Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda.

K Seden, C Merry, R Hewson, M Siccardi, M Lamorde, P Byakika-Kibwika, E Laker, R Parkes-Ratanshi, D J Back, S H Khoo

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

K SedenDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK k.seden@liv.ac.uk.
C MerryInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin 2, Ireland.
R HewsonDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
M SiccardiDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
M LamordeInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin 2, Ireland.
P Byakika-KibwikaInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda Department of Pharmacology and Therapeutics, Trinity College Dublin, Dublin 2, Ireland.
E LakerInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
R Parkes-RatanshiInfectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
D J BackDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
S H KhooDepartment of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK.
University of Liverpool · GBMakerere University · UGInfectious Diseases Institute · UG

Funding

Medical Research Council MR/L012413/1
6 · The paper itself

Abstract

objectivesScale-up of HIV services in sub-Saharan Africa has rapidly increased, necessitating evaluation of medication safety in these settings. Drug-drug interactions (DDIs) involving antiretrovirals (ARVs) in sub-Saharan Africa are poorly characterized. We evaluated the prevalence and type of ARV DDIs in Ugandan outpatients and identified the patients most at risk.

methodsA total of 2000 consecutive patients receiving ARVs at the Infectious Diseases Institute, Kampala were studied. The most recent prescription for each patient was screened for clinically significant DDIs using www.hiv-druginteractions.org. Univariable and multivariable logistic regression were used to identify risk factors for DDIs. A screening tool was developed using significant risk factors and tested in a further 500 patients.

resultsClinically significant DDIs were observed in 374 (18.7%) patients, with a total of 514 DDIs observed. Only 0.2% of DDIs involved a contraindicated combination. Comedications commonly associated with DDIs were antibiotics (4.8% of 2000 patients), anthelmintics (2.2%) and antifungals (3.5%). Patient age, gender, CD4 count and weight did not affect risk of DDIs. In multivariable analysis, the patient factors that independently increased risk of DDIs were two or more comedications (P < 0.0001), a PI-containing ARV regimen (P < 0.0001), use of an anti-infective (P < 0.0001) and WHO clinical stage 3-4 (P = 0.04). A scoring system based on having at least two of these risk factors identified between 75% and 90% of DDIs in a validation cohort.

conclusionsSignificant ARV DDIs occur at similar rates in resource-limited settings and developed countries; however, the comedications frequently causing DDIs differ. Development of tools that are relevant to particular settings should be a priority to assist with prevention and management of DDIs.

Indexed as

AdultAmbulatory Care FacilitiesAnti-Infective AgentsAnti-Retroviral AgentsDrug InteractionsFemaleHIV InfectionsHumansMaleMiddle AgedPrevalenceRetrospective StudiesUgandaAnti-Infective AgentsAnti-Retroviral Agents

Identifiers

PMID26286575
PMCPMC4652684
OpenAlexW1941431672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.